Trial Profile

A clinical trial assessing FLAG 003

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FLAG-003 (Primary)
Indications Diffuse intrinsic pontine glioma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

16 Jul 2024 According to a FLAG Therapeutics media release, in May 2024 FLAG Therapeutics conducted a successful Type B meeting with the FDA regarding FLAG-003 and intends to file an Investigational New Drug (IND) application in the fourth quarter of 2024 and to initiate Phase 1 clinical studies in DIPG in early 2025.
03 Feb 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com